About Mission

Overview

Mission Therapeutics is a world leader in developing novel therapeutics which combat serious diseases including Parkinson’s Disease by enhancing mitophagy – the vital quality control process cells use to ensure dysfunctional mitochondria are removed.

Vision

Our vision is to transform the treatment of serious illnesses by harnessing our world class knowledge of disease-associated deubiquitylating enzymes (DUBs) to create a new class of drugs.

Mission’s key focus is on small molecules which promote mitophagy, and thus improve overall cellular health, by inhibiting a DUB called USP30.

Patient focused

Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including Parkinson’s Disease (PD), Duchenne muscular dystrophy (DMD), other neuro-degenerative diseases, heart and kidney diseases, fibrosis, and rare mitochondria diseases, by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).

Why DUBs?

DUBs comprise a group of around 100 human proteins that play important roles in regulating ubiquitylation. This is the process whereby ubiquitin – a small, regulatory protein so called because it is present in all complex organisms and virtually every cell in the body – controls protein homeostasis, protein activity, intracellular location, and sub-cellular turnover or degradation.

Certain DUBs such as USP30 play a critical role in regulating mitophagy, but they can sometimes inhibit this process to such an extent that they negatively impact the health of the cell.

World-leading DUB platform

Mission Therapeutics has built a proprietary world-leading DUB platform that combines novel disease biology, bespoke screening tools and unique chemistry, thereby generating a rich pipeline of highly potent and selective small-molecule drug candidates that have substantial clinical and commercial potential. The Company’s USP30 program is now in clinical development.

Blue chip investors

To date the Company has received £73 million / $101 million in venture capital from a blue chip syndicate comprising institutional and corporate investors that include: IP Group plc, Rosetta Capital, Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.

Experienced leadership team

Mission’s leadership team has a wealth of international, commercial and scientific experience. The Company has a collaborative, science-driven culture and has strong collaborations with key academic and research centres. These include the Michael J Fox Foundation, the Gurdon Institute Cancer Research UK Laboratories at the University of Cambridge, the Oxford Parkinson’s Disease Centre at the University of Oxford, and the Wellcome Trust Mitochondrial Research Centre at Newcastle University.

Location

Founded in 2011, Mission Therapeutics is based at the Babraham Research Campus in Cambridge, UK.

Click here for a tour of our office and labs and to watch BioMed Realty’s grand opening of the Glenn Berge Building, located on Babraham Research Campus. Mission Therapeutics re-located to these new premises in May 2020.

Key Facts

  • List Title 1

    Lorem ipsum dolor sit amet, integre evertitur usu in, sit nonumy detraxit ei. Te placerat interesset vis. Ut nec gubergren

  • List Title 2

    Lorem ipsum dolor sit amet, integre evertitur usu in, sit nonumy detraxit ei. Te placerat interesset vis. Ut nec gubergren

  • List Title 3

    Lorem ipsum dolor sit amet, integre evertitur usu in, sit nonumy detraxit ei. Te placerat interesset vis. Ut nec gubergren

Mission Therapeutics © website by Instinctif Partners